Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study.
Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study.
复制标题
以非视神经脊髓表现为首发症状的视神经脊髓炎谱系疾病:一项长期观察研究
DOI:
10.1186/s12883-021-02059-1
复制
发表时间:
2021-01-25
期刊:
影响因子:
2.6
通讯作者:
Yang Z
中科院分区:
文献类型:
--
作者:
Li R;Lu D;Li H;Wang Y;Shu Y;Chang Y;Sun X;Lu Z;Qiu W;Yang Z
BackgroundEarly stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, the clinical characteristics and long-term outcomes of these patients remain unknown. We sought to analyze the clinical characteristics, imaging features, and long-term outcomes of NMOSD with non-opticospinal manifestations as initial symptoms.MethodsWe retrospectively included relevant patients from our center. Clinical, demographic, magnetic resonance imaging, treatment, and outcome data were compared according to the non-opticospinal vs. opticospinal initial symptoms.ResultsWe identified 43 (9.13 %) patients with non-opticospinal initial symptoms among 471 patients with NMOSD. Of these, 88.37 % developed optic neuritis/myelitis during an average follow-up period of 6.33 years. All the non-opticospinal symptoms were brain/brainstem symptoms. Most of the symptoms and associated brain lesions were reversible. These patients had a younger onset age (P< 0.001), lower serum aquaporin-4 (AQP4) antibody titers (P= 0.030), and a lower Expanded Disability Status Scale (EDSS) score at onset (P< 0.001) and follow-up (P= 0.041) than NMOSD patients with opticospinal initial symptoms. In addition, EDSS scores reached 3.0 (indicating moderate disability) later than in patients with opticospinal initial symptoms (P= 0.028).ConclusionsPatients with NMOSD with non-opticospinal initial symptoms have a younger onset age, lower serum AQP4 antibody titers, and better clinical outcomes.
登录
查看更多内容
影响因子:
9.9
作者:
Wingerchuk DM;Banwell B;Bennett JL;Cabre P;Carroll W;Chitnis T;de Seze J;Fujihara K;Greenberg B;Jacob A;Jarius S;Lana-Peixoto M;Levy M;Simon JH;Tenembaum S;Traboulsee AL;Waters P;Wellik KE;Weinshenker BG;International Panel for NMO Diagnosis
通讯作者:
International Panel for NMO Diagnosis
影响因子:
9.9
作者:
Wingerchuk, D. M.;Lennon, V. A.;Weinshenker, B. G.
通讯作者:
Weinshenker, B. G.
影响因子:
14.5
作者:
Kitley, Joanna;Leite, M. Isabel;Palace, Jacqueline
通讯作者:
Palace, Jacqueline
影响因子:
168.9
作者:
Lennon, VA;Wingerchuk, DM;Weinshenker, BG
通讯作者:
Weinshenker, BG
影响因子:
2.6
作者:
Mao Z;Yin J;Zhong X;Zhao Z;Qiu W;Lu Z;Hu X
通讯作者:
Hu X